Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression

Peroxisome proliferator-activated receptor- (PPAR-) γ is a ligand-dependent transcription factor, and it has become evident that PPAR-γ agonists have renoprotective effects, but their influence and mechanism during the development of calcium oxalate (CaOx) nephrolithiasis remain unknown. Rosiglitazo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ya-Dong, Yu, Shi-Liang, Wang, Rui, Liu, Jian-Nan, Jin, Yin-Shan, Li, Yi-Fu, An, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875173/
https://www.ncbi.nlm.nih.gov/pubmed/31781338
http://dx.doi.org/10.1155/2019/4826525
_version_ 1783472969391013888
author Liu, Ya-Dong
Yu, Shi-Liang
Wang, Rui
Liu, Jian-Nan
Jin, Yin-Shan
Li, Yi-Fu
An, Rui-Hua
author_facet Liu, Ya-Dong
Yu, Shi-Liang
Wang, Rui
Liu, Jian-Nan
Jin, Yin-Shan
Li, Yi-Fu
An, Rui-Hua
author_sort Liu, Ya-Dong
collection PubMed
description Peroxisome proliferator-activated receptor- (PPAR-) γ is a ligand-dependent transcription factor, and it has become evident that PPAR-γ agonists have renoprotective effects, but their influence and mechanism during the development of calcium oxalate (CaOx) nephrolithiasis remain unknown. Rosiglitazone (RSG) was used as a representative PPAR-γ agonist in our experiments. The expression of transforming growth factor-β1 (TGF-β1), hepatocyte growth factor (HGF), c-Met, p-Met, PPAR-γ, p-PPAR-γ (Ser112), Smad2, Smad3, pSmad2/3, and Smad7 was examined in oxalate-treated Madin-Darby canine kidney (MDCK) cells and a stone-forming rat model. A CCK-8 assay was used to evaluate the effects of RSG on cell viability. In addition, intracellular reactive oxygen species (ROS) levels were monitored, and lipid peroxidation in renal tissue was detected according to superoxide dismutase and malondialdehyde levels. Moreover, the location and extent of CaOx crystal deposition were evaluated by Pizzolato staining. Our results showed that, both in vitro and in vivo, oxalate impaired PPAR-γ expression and phosphorylation, and then accumulative ROS production was observed, accompanied by enhanced TGF-β1 and reduced HGF. These phenomena could be reversed by the addition of RSG. RSG also promoted cell viability and proliferation and decreased oxidative stress damage and CaOx crystal deposition. However, these protective effects of RSG were abrogated by the PPAR-γ-specific inhibitor GW9662. Our results revealed that the reduction of PPAR-γ activity played a critical role in oxalate-induced ROS damage and CaOx stone formation. RSG can regulate TGF-β1 and HGF/c-Met through PPAR-γ to exert antioxidant effects against hyperoxaluria and alleviate crystal deposition. Therefore, PPAR-γ agonists may be expected to be a novel therapy for nephrolithiasis, and this effect is related to PPAR-γ-dependent suppression of oxidative stress.
format Online
Article
Text
id pubmed-6875173
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68751732019-11-28 Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression Liu, Ya-Dong Yu, Shi-Liang Wang, Rui Liu, Jian-Nan Jin, Yin-Shan Li, Yi-Fu An, Rui-Hua Oxid Med Cell Longev Research Article Peroxisome proliferator-activated receptor- (PPAR-) γ is a ligand-dependent transcription factor, and it has become evident that PPAR-γ agonists have renoprotective effects, but their influence and mechanism during the development of calcium oxalate (CaOx) nephrolithiasis remain unknown. Rosiglitazone (RSG) was used as a representative PPAR-γ agonist in our experiments. The expression of transforming growth factor-β1 (TGF-β1), hepatocyte growth factor (HGF), c-Met, p-Met, PPAR-γ, p-PPAR-γ (Ser112), Smad2, Smad3, pSmad2/3, and Smad7 was examined in oxalate-treated Madin-Darby canine kidney (MDCK) cells and a stone-forming rat model. A CCK-8 assay was used to evaluate the effects of RSG on cell viability. In addition, intracellular reactive oxygen species (ROS) levels were monitored, and lipid peroxidation in renal tissue was detected according to superoxide dismutase and malondialdehyde levels. Moreover, the location and extent of CaOx crystal deposition were evaluated by Pizzolato staining. Our results showed that, both in vitro and in vivo, oxalate impaired PPAR-γ expression and phosphorylation, and then accumulative ROS production was observed, accompanied by enhanced TGF-β1 and reduced HGF. These phenomena could be reversed by the addition of RSG. RSG also promoted cell viability and proliferation and decreased oxidative stress damage and CaOx crystal deposition. However, these protective effects of RSG were abrogated by the PPAR-γ-specific inhibitor GW9662. Our results revealed that the reduction of PPAR-γ activity played a critical role in oxalate-induced ROS damage and CaOx stone formation. RSG can regulate TGF-β1 and HGF/c-Met through PPAR-γ to exert antioxidant effects against hyperoxaluria and alleviate crystal deposition. Therefore, PPAR-γ agonists may be expected to be a novel therapy for nephrolithiasis, and this effect is related to PPAR-γ-dependent suppression of oxidative stress. Hindawi 2019-11-12 /pmc/articles/PMC6875173/ /pubmed/31781338 http://dx.doi.org/10.1155/2019/4826525 Text en Copyright © 2019 Ya-Dong Liu et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liu, Ya-Dong
Yu, Shi-Liang
Wang, Rui
Liu, Jian-Nan
Jin, Yin-Shan
Li, Yi-Fu
An, Rui-Hua
Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression
title Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression
title_full Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression
title_fullStr Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression
title_full_unstemmed Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression
title_short Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression
title_sort rosiglitazone suppresses calcium oxalate crystal binding and oxalate-induced oxidative stress in renal epithelial cells by promoting ppar-γ activation and subsequent regulation of tgf-β1 and hgf expression
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875173/
https://www.ncbi.nlm.nih.gov/pubmed/31781338
http://dx.doi.org/10.1155/2019/4826525
work_keys_str_mv AT liuyadong rosiglitazonesuppressescalciumoxalatecrystalbindingandoxalateinducedoxidativestressinrenalepithelialcellsbypromotingppargactivationandsubsequentregulationoftgfb1andhgfexpression
AT yushiliang rosiglitazonesuppressescalciumoxalatecrystalbindingandoxalateinducedoxidativestressinrenalepithelialcellsbypromotingppargactivationandsubsequentregulationoftgfb1andhgfexpression
AT wangrui rosiglitazonesuppressescalciumoxalatecrystalbindingandoxalateinducedoxidativestressinrenalepithelialcellsbypromotingppargactivationandsubsequentregulationoftgfb1andhgfexpression
AT liujiannan rosiglitazonesuppressescalciumoxalatecrystalbindingandoxalateinducedoxidativestressinrenalepithelialcellsbypromotingppargactivationandsubsequentregulationoftgfb1andhgfexpression
AT jinyinshan rosiglitazonesuppressescalciumoxalatecrystalbindingandoxalateinducedoxidativestressinrenalepithelialcellsbypromotingppargactivationandsubsequentregulationoftgfb1andhgfexpression
AT liyifu rosiglitazonesuppressescalciumoxalatecrystalbindingandoxalateinducedoxidativestressinrenalepithelialcellsbypromotingppargactivationandsubsequentregulationoftgfb1andhgfexpression
AT anruihua rosiglitazonesuppressescalciumoxalatecrystalbindingandoxalateinducedoxidativestressinrenalepithelialcellsbypromotingppargactivationandsubsequentregulationoftgfb1andhgfexpression